...
首页> 外文期刊>BMC research notes >Body iron status of children and adolescents with transfusion dependent β-thalassaemia: trends of serum ferritin and associations of optimal body iron control
【24h】

Body iron status of children and adolescents with transfusion dependent β-thalassaemia: trends of serum ferritin and associations of optimal body iron control

机译:输血依赖型β地中海贫血的儿童和青少年的体内铁状况:血清铁蛋白的趋势和最佳体内铁控制的关联

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Abstract ObjectiveThis cross sectional study aims to describe the body iron status, trends of serum ferritin and associations of optimal body iron control in patients aged below 16?years with transfusion dependent β-thalassaemia attending Paediatric and Adolescent Thalassaemia Centres of the Colombo North Teaching Hospital of Sri Lanka.ResultsOut of 54 children, 51% were males and a majority were aged 11–16?years; 83% had β-thalassaemia major while 13% had HbE β-thalassaemia. Mean serum ferritin was 1778(±?1458)?μg/l and 29% had optimal serum ferritin (below 1000?μg/l). Trend of mean serum ferritin over time showed gradual decline between 2011 and 2017 and longitudinal trend of individual patients at yearly intervals showed gradual rise until 5?years of age and plateauing thereafter. All except two patients were receiving iron chelator medication of which the most commonly used was oral deferasirox (92%). The most common iron-related complications were short stature (24.1%) and pubertal delay (42.8% of??14?years). None of the patients had hypothyroidism, hypoparathyroidism or diabetes. Optimal serum ferritin levels were significantly associated with the diagnosis of thalassaemia at a later age (23.6 vs 9.0?months) and higher family income (OR-4.81;95%CI 1.17–19.67) however was not associated with the age of the patient or duration of transfusion.
机译:摘要目的本横断面研究旨在描述在科伦坡北部教学医院儿科和青少年地中海贫血症中心接受输血依赖的β地中海贫血的16岁以下患者中16岁以下患者的体内铁状况,血清铁蛋白趋势以及最佳体内铁控制的关联斯里兰卡。结果在54名儿童中,有51%是男性,大部分年龄在11-16岁。 83%的患者患有严重的β地中海贫血,而13%的患者患有HbEβ地中海贫血。平均血清铁蛋白为1778(±?1458)?μg/ l,有29%的最佳血清铁蛋白(低于1000?μg/ l)。平均血清铁蛋白随时间的变化趋势在2011年至2017年间逐渐下降,个别患者的纵向趋势按年间隔显示逐渐上升,直至5岁,此后趋于平稳。除两名患者外,所有患者均接受铁螯合剂药物治疗,其中最常用的是口服地拉罗司(92%)。最常见的与铁有关的并发症是身材矮小(24.1%)和青春期延迟(≥14岁者的42.8%)。没有患者有甲状腺功能减退,甲状旁腺功能低下或糖尿病。最佳血清铁蛋白水平与地中海贫血的诊断与年龄较高(23.6 vs 9.0?months)和较高的家庭收入(OR-4.81; 95%CI 1.17-19.67)显着相关,但与患者年龄或年龄无关。输血时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号